ReviewClinical microbiology reviews2007
Viral determinants of resistance to treatment in patients with hepatitis C.
Review in Clinical microbiology reviews, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 157 citations in OpenAlex.
- Prediction of prognostic biomarkers for interferon-based therapy to hepatitis C virus patients: a meta-analysis of the NS5A protein in subtypes 1a, 1b, and 3a.Virology journal · 2010Pooled it
- Trial
- Trial
- Review
- The Presence of Autoantibodies to Cytoplasmic Rod and Ring Particles in the Serum of Patients with Chronic Hepatitis C Virus Infection.Hepatitis monthly · 2016Article
- Analysis of mutations in the core and NS5A genes of hepatitis C virus in non-responder and relapser patients after treatment with Peg-IFN-α and ribavirin.Virusdisease · 2016Article
- Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection.Cellular & molecular immunology · 2016Review
- The role of HCV proteins on treatment outcomes.Virology journal · 2015Review
- Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy.International journal of molecular sciences · 2015Article
- Influence of host resistance on viral adaptation: hepatitis C virus as a case study.Infection and drug resistance · 2015Review
- Interferon alpha induced intrahepatic pSTAT1 inversely correlate with serum HCV RNA levels in chronic HCV infection.Experimental and molecular pathology · 2014Article
- Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling.Antiviral therapy · 2014Article
- Anti-tumor effect of ribavirin in combination with interferon-α on renal cell carcinoma cell lines in vitro.Cancer cell international · 2014Article
- Protein kinase expression as a predictive factor for interferon response in chronic hepatitis C patients.Journal of advanced research · 2014Article
- Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents.Hepatic medicine : evidence and research · 2014Review
- Article
- Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance.Journal of virology · 2013Article
- Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype.Journal of virology · 2013Article
- Clinical impact of hepatitis B and C virus envelope glycoproteins.World journal of gastroenterology · 2013Review
- What are the promising new therapies in the field of chronic hepatitis C after the first-generation direct-acting antivirals?Current gastroenterology reports · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hepatitis C virus (HCV) infection affects more than 170 million persons worldwide and is responsible for the development of liver cirrhosis in many cases. Standard treatment with pegylated alpha interferon (IFN-alpha) in combination with the nucleoside analogue ribavirin leads to a sustained virologic response in approximately half of the patients. IFN-alpha is classified as an indirect treatment, as it interacts with the host's immune response. The mechanism of action of ribavirin is still unknown. The benefit of triple therapy by adding other antiviral agents, e.g., amantadine, is controversial. Currently, new direct antiviral drugs (HCV protease/polymerase inhibitors) are being evaluated in phase 1/phase 2 trials. Phenotypic resistance to antiviral therapy has been attributed to amino acid variations within distinct regions of the HCV polyprotein. While sensitivity to IFN-alpha-based antiviral therapy in vivo is clearly correlated with the number of mutations within the HCV NS5A protein, the underlying functional mechanisms for this association are unknown. In turn, in vitro, several mechanisms to circumvent the host immune defense or to block treatment-induced antiviral activities have been described for different HCV proteins. By the introduction of direct antiviral drugs, hepatitis C therapy now is entering a new era in which the development of resistance may become the most important parameter for treatment success or failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.